{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T22:48:39Z","timestamp":1775861319272,"version":"3.50.1"},"reference-count":44,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Pemphigus vulgaris (PV) is a rare autoimmune blistering disease caused by IgG au-toantibodies against desmoglein 1 and\/or desmoglein 3, leading to flaccid blisters on the skin and mucous membranes. The course of PV during pregnancy represents a special clinical challenge due to immunological changes accompanying physiological immunosuppression and the need to protect the developing fetus. Materials and Methods: To analyze the current state of knowledge, a literature review was performed covering the years 2015\u20132025. Publications describing PV diagnosed during pregnancy or in neonates were screened, and nine case reports discussing ten patients meeting the inclusion criteria were selected for detailed analysis. In this study, we also present our own clinical case of PV in pregnancy to complement the literature review and provide practical insight into disease management. Results: In most cases, the disease was diagnosed in the first trimester of pregnancy, and the most common symptoms were flaccid blisters and erosions of the oral mucosa. The diagnosis was confirmed by direct immunofluorescence (DIF) and ELISA testing. The first-line treatment remained systemic glucocorticosteroids (GCS), mainly prednisolone, which is considered the safest. In resistant cases, intravenous immunoglobulins (IVIg) were used, which were considered effective and safe, though their use may limit the transplacental transfer of autoantibodies to the fetus. In newborns, the symptoms rarely occurred, were mild, and resolved spontaneously. Drugs with proven teratogenic effects, such as methotrexate, cyclophosphamide, and mycophenolate mofetil, are contraindicated during pregnancy. In the case of rituximab therapy, it is recommended to postpone pregnancy for at least 12 months after the completion of treatment to minimize the potential risk of immunosuppression in the newborn. Conclusions: The treatment of PV during pregnancy requires close interdisciplinary cooperation. Therapy should be carefully individualized, taking into account both therapeutic efficacy and fetal safety. Perhaps then, pregnancy-related pemphigus diseases, given their peculiarities, should be classified as a distinct variety within the desmosomal type of autoimmune blistering diseases.<\/jats:p>","DOI":"10.3390\/medicina62010031","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T14:27:47Z","timestamp":1766500067000},"page":"31","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["An Update on Pemphigus Vulgaris in Pregnancy and Neonates: Management Options and Our Clinical-Laboratory Experience"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5417-1075","authenticated-orcid":false,"given":"Maksymilian","family":"Markwitz","sequence":"first","affiliation":[{"name":"Autoimmune Blistering Dermatoses Section, Department of Dermatology, Poznan University of Medical Sciences, 60-355 Poznan, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7736-3219","authenticated-orcid":false,"given":"Natalia","family":"Welc","sequence":"additional","affiliation":[{"name":"Autoimmune Blistering Dermatoses Section, Department of Dermatology, Poznan University of Medical Sciences, 60-355 Poznan, Poland"},{"name":"Doctoral School, Poznan University of Medical Sciences, 60-812 Poznan, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8221-7622","authenticated-orcid":false,"given":"Monika","family":"Bowszyc-Dmochowska","sequence":"additional","affiliation":[{"name":"Cutaneous Histopathology and Immunopathology Section, Department of Dermatology, Poznan University of Medical Sciences, 60-355 Poznan, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8191-7475","authenticated-orcid":false,"given":"Magdalena","family":"Ja\u0142owska","sequence":"additional","affiliation":[{"name":"Autoimmune Blistering Dermatoses Section, Department of Dermatology, Poznan University of Medical Sciences, 60-355 Poznan, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4819-2051","authenticated-orcid":false,"given":"Marian","family":"Dmochowski","sequence":"additional","affiliation":[{"name":"Autoimmune Blistering Dermatoses Section, Department of Dermatology, Poznan University of Medical Sciences, 60-355 Poznan, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(05)66829-8","article-title":"Pemphigus","volume":"366","author":"Bystryn","year":"2005","journal-title":"Lancet"},{"key":"ref_2","unstructured":"Freedberg, I.M., and Fitzpatrick, T.B. (1999). Fitzpatrick\u2019s Dermatology in General Medicine, McGraw-Hill, Health Professions Division."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Dmochowski, M., Ja\u0142owska, M., and Bowszyc-Dmochowska, M. (2022). Issues Occupying Our Minds: Nomenclature of Autoimmune Blistering Diseases Requires Updating, Pemphigus Vulgaris Propensity to Affect Areas Adjacent to Natural Body Orifices Unifies Seemingly Diverse Clinical Features of This Disease. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1103375"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7658","DOI":"10.1073\/pnas.87.19.7658","article-title":"Major Histocompatibility Complex Haplotype Studies in Ashkenazi Jewish Patients with Pemphigus Vulgaris","volume":"87","author":"Ahmed","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5056","DOI":"10.1073\/pnas.88.11.5056","article-title":"Major Histocompatibility Complex Haplotypes and Class II Genes in Non-Jewish Patients with Pemphigus Vulgaris","volume":"88","author":"Ahmed","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1006\/jaut.2000.0388","article-title":"HLA Class II Polymorphism Contributes to Specify Desmoglein Derived Peptides in Pemphigus Vulgaris and Pemphigus Foliaceus","volume":"15","author":"Loiseau","year":"2000","journal-title":"J. Autoimmun."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.abd.2020.10.007","article-title":"Autoimmune Bullous Diseases in Pregnancy: Clinical and Epidemiological Characteristics and Therapeutic Approach","volume":"96","author":"Fagundes","year":"2021","journal-title":"An. Bras. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1600-0897.2010.00852.x","article-title":"REVIEW ARTICLE: Th1\/Th2\/Th17 and Regulatory T-Cell Paradigm in Pregnancy","volume":"63","author":"Saito","year":"2010","journal-title":"Am. J. Reprod. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/cmi.2012.40","article-title":"Pre-Treatment with IL-1\u03b2 Enhances the Efficacy of MSC Transplantation in DSS-Induced Colitis","volume":"9","author":"Fan","year":"2012","journal-title":"Cell Mol. Immunol."},{"key":"ref_10","first-page":"170","article-title":"Pregnancy-Triggered Maternal Pemphigus Vulgaris with Persistent Gingival Lesions","volume":"19","author":"Dmochowski","year":"2011","journal-title":"Acta Dermatovenerol. Croat."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"100004","DOI":"10.1016\/j.xjidi.2021.100004","article-title":"Epidemiology of Pemphigus","volume":"1","author":"Kridin","year":"2021","journal-title":"JID Innov."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1525-1470.1986.tb00653.x","article-title":"Neonatal Pemphigus Vulgaris: Trsmtel Transmission of Antibodies","volume":"3","author":"Hup","year":"1986","journal-title":"Pediatr. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1046\/j.1365-4362.1999.00764.x","article-title":"Childhood, Neonatal, and Stillborn Pemphigus Vulgaris","volume":"38","author":"Bjarnason","year":"1999","journal-title":"Int. J. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1038\/sj.jid.5700388","article-title":"Prevalence of Anti-Desmoglein-3 Antibodies in Endemic Regions of Fogo Selvagem in Brazil","volume":"126","author":"Dasher","year":"2006","journal-title":"J. Investig. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e259305","DOI":"10.1136\/bcr-2023-259305","article-title":"Neonatal Pemphigus Vulgaris","volume":"17","author":"Aiholli","year":"2024","journal-title":"BMJ Case Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e8343","DOI":"10.1002\/ccr3.8343","article-title":"Pemphigus Vulgaris in a Neonate Born to a Mother with Pemphigus Vulgaris: A Case Report","volume":"11","author":"Anand","year":"2023","journal-title":"Clin. Case Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ajog.2023.05.032","article-title":"Periumbilical Blisters: Pemphigus Vulgaris During Pregnancy","volume":"229","author":"Kano","year":"2023","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e05734","DOI":"10.1002\/ccr3.5734","article-title":"Pregnancy-Triggered Pemphigus Vulgaris with Favorable Fetal Outcomes: A Case Report","volume":"10","author":"Mohaghegh","year":"2022","journal-title":"Clin. Case Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e13187","DOI":"10.1111\/dth.13187","article-title":"Efficacious Treatment of Pemphigus Vulgaris by Intravenous Immunoglobulin During Pregnancy and Postpartum Period","volume":"33","author":"Bostan","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/ijd.14513","article-title":"New Onset Bullae in a Pregnant Woman","volume":"59","author":"Bray","year":"2020","journal-title":"Int. J. Dermatol."},{"key":"ref_21","first-page":"10","article-title":"Polycyclic Annular Presentation of Pemphigus Vulgaris with an Eosinophil Predominance in Two Pregnant Patients","volume":"24","author":"Sun","year":"2018","journal-title":"Dermatol. Online J."},{"key":"ref_22","first-page":"13030","article-title":"Concomitant Pemphigus Vulgaris and Pemphigoid Gestationis: A Case Report and Review of the Literature","volume":"22","author":"Vin","year":"2016","journal-title":"Dermatol. Online J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e101-2","DOI":"10.7812\/TPP\/15-059","article-title":"Pregnancy-Associated \u201cCutaneous Type\u201d Pemphigus Vulgaris","volume":"20","author":"Rangel","year":"2016","journal-title":"Perm J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/cup.14835","article-title":"Clinical, Serologic, and Histopathologic Features of Patients With Pemphigus With Either Positive or Negative IgG4 Intercellular Deposition by Direct Immunofluorescence (DIF): A Retrospective Case\u2013Control Study of 55 DIF Biopsy Specimens","volume":"52","author":"Garbanzos","year":"2025","journal-title":"J. Cutan Pathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"373","DOI":"10.5114\/ada.2025.153492","article-title":"Effectiveness of Direct Immunofluorescence for Diagnosing Autoimmune Bullous Diseases: Data from the Central European Referral Department","volume":"42","author":"Falkowski","year":"2025","journal-title":"Adv. Dermatol. Allergol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/DAD.0000000000001516","article-title":"Practical Direct Immunofluorescence","volume":"42","author":"Kim","year":"2020","journal-title":"Am. J. Dermatopathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"689","DOI":"10.5114\/dr.2023.136328","article-title":"Pemphigus Foliaceus in an Elderly Woman: Advantages and Limitations of Histopathology in Pemphigus","volume":"110","author":"Falkowski","year":"2023","journal-title":"Dermatol. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1001\/archderm.144.6.783","article-title":"Do Safe and Effective Treatment Options Exist for Patients With Active Pemphigus Vulgaris Who Plan Conception and Pregnancy?","volume":"144","author":"Lehman","year":"2008","journal-title":"Arch. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Genovese, G., Derlino, F., Berti, E., and Marzano, A.V. (2020). Treatment of Autoimmune Bullous Diseases During Pregnancy and Lactation: A Review Focusing on Pemphigus and Pemphigoid Gestationis. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.583354"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.intimp.2017.10.027","article-title":"Current and Future Treatment Options for Pemphigus: Is It Time to Move Towards More Effective Treatments?","volume":"53","author":"Tavakolpour","year":"2017","journal-title":"Int. Immunopharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"adv00535","DOI":"10.2340\/00015555-3831","article-title":"Survival of Adjuvant Drugs for Treatment of Pemphigus: A Population-Based Cohort Study","volume":"101","author":"Kridin","year":"2021","journal-title":"Acta Derm. Venereol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/j.1468-3083.2010.03925.x","article-title":"Use of Intravenous Immunoglobulin Therapy During Pregnancy in Patients with Pemphigus Vulgaris","volume":"25","author":"Ahmed","year":"2011","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e056","DOI":"10.1097\/JW9.0000000000000056","article-title":"Burden of Pemphigus Vulgaris with a Particular Focus on Women: A Review","volume":"8","author":"Kianfar","year":"2022","journal-title":"Int. J. Womens Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/jdv.16752","article-title":"Updated S2K Guidelines on the Management of Pemphigus Vulgaris and Foliaceus Initiated by the European Academy of Dermatology and Venereology (EADV)","volume":"34","author":"Joly","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa2028564","article-title":"Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris","volume":"384","author":"Werth","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Mi\u0161e, J., Juki\u0107, I.L., and Marinovi\u0107, B. (2022). Rituximab\u2014Progress but Still Not a Final Resolution for Pemphigus Patients: Clinical Report From a Single Center Study. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.884931"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"rkaa074","DOI":"10.1093\/rap\/rkaa074","article-title":"Pregnancy Outcomes Following Maternal Treatment with Rituximab Prior to or during Pregnancy: A Case Series","volume":"5","author":"Perrotta","year":"2021","journal-title":"Rheumatol. Adv. Pr."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Gklinos, P., and Dobson, R. (2023). Monoclonal Antibodies in Pregnancy and Breastfeeding in Patients with Multiple Sclerosis: A Review and an Updated Clinical Guide. Pharmaceuticals, 16.","DOI":"10.3390\/ph16050770"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Beltagy, A., Aghamajidi, A., Trespidi, L., Ossola, W., and Meroni, P.L. (2021). Biologics During Pregnancy and Breastfeeding Among Women With Rheumatic Diseases: Safety Clinical Evidence on the Road. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.621247"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e038","DOI":"10.1097\/JW9.0000000000000038","article-title":"Pregnancy Outcomes in Women with Pemphigus Exposed to Rituximab Before or During Pregnancy","volume":"8","author":"Dehghanimahmoudabadi","year":"2022","journal-title":"Int. J. Womens Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2008\/271363","article-title":"Rituximab Administration in Third Trimester of Pregnancy Suppresses Neonatal B-Cell Development","volume":"2008","author":"Klink","year":"2008","journal-title":"Clin. Dev. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1093\/rheumatology\/kev404","article-title":"BSR and BHPR Guideline on Prescribing Drugs in Pregnancy and Breastfeeding\u2014Part I: Standard and Biologic Disease Modifying Anti-Rheumatic Drugs and Corticosteroids: Table 1","volume":"55","author":"Flint","year":"2016","journal-title":"Rheumatology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"749","DOI":"10.4103\/idoj.idoj_632_23","article-title":"Pemphigus and Pregnancy","volume":"15","author":"De","year":"2024","journal-title":"Indian Dermatol. Online J."},{"key":"ref_44","first-page":"166","article-title":"Trauma-induced Pemphigus: A Case Series of 36 Patients","volume":"14","author":"Daneshpazhooh","year":"2016","journal-title":"JDDG J. Dtsch. Dermatol. Ges."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/1\/31\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T05:59:10Z","timestamp":1766987950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/1\/31"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["medicina62010031"],"URL":"https:\/\/doi.org\/10.3390\/medicina62010031","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]}}}